Company
Syntara Ltd
ASX:PXS
Syntara Ltd is a clinical-stage drug development company focused on the development of novel therapeutics aimed at correcting extracellular matrix (ECM) dysfunction. This will lead to positive outcomes in a range of diseases with high unmet need, including haematological malignancies such as myelofibrosis and myelodysplastic syndrome, chronic fibrosis (including skin scarring, pulmonary fibrosis, chronic kidney disease, NASH and cardiac fibrosis) and neuroinflammation.
175 stories · page 2 of 9
Pharmaxis receives interim data for Phase 2 cancer trial
The company is also raising $10 million in a two-tranche placement to a small group of international and domestic institutional investors.
Pharmaxis fields promising interim data from skin scarring treatment study assessing PXS-6302
“We will now work with UWA to design a follow up study that will address the need for objective endpoints to meet anticipated regulatory hurdles and explore further indications that suit the profile of PXS-6302," said CEO Gary Phillips.
Pharmaxis to tackle Parkinson’s in “groundbreaking” clinical collaboration
“This study provides hope for an effective treatment and a step towards the longer-term goal of stopping neurodegeneration,” said Pharmaxis CEO Gary Phillips.
Pharmaxis strikes a US$5 million deal with Aptar Pharma on Orbital drug delivery technology
Global drug delivery company Aptar Pharma has exercised its option for a worldwide licence on the Pharmaxis Orbital technology for US$2.5 million and a subsequent option for an outright purchase of the technology for a further US$2.5 millio
Pharmaxis appoints 20-year veteran as Chief Medical Officer
Pharmaxis has appointed Dr Jana Baskar to the role of Chief Medical Officer. Dr Baskar will bring strong oversight to the clinical stage drug development company.
Pharmaxis to host research and development showcase webinars for leading drug discoveries
Pharmaxis will host several presentations showcasing the company's leading drug discoveries and their applications. The webinars are free to access and recordings will be available on the Pharmaxis website.
Pharmaxis launches five new clinical trial sites in phase 2 bone marrow cancer trial
“This planned initiation of new trial sites in Taiwan will bring the total number of active sites to 16. The study is making pleasing progress as it builds to a recruitment target of 24 patients. This latest expansion of sites is part of a
Pharmaxis confident of capturing global market for scar reduction with first patients dosed in study
The collaboration with the research team led by Professor Fiona Wood AM has dosed the first patients in a trial of 50 patients with established scars.
Pharmaxis discoveries to get a A$1.4 million boost to advance cancer and skin disease treatments
“Together, our work aims to support commercialisation of new treatment approaches for pancreatic cancer and various skin diseases, which we hope will deliver significant benefits for patients,” PXS CEO Gary Phillips said.
Pharmaxis’ oversubscribed share purchase plan raises $2.6 million
The clinical-stage drug development company opted to increase its raise target from A$2 million after receiving eligible applications for A$2.585 million worth of shares.
Pharmaxis stocks rising with new drugs coming online in 2022, says broker
Among a range of factors for the outperform recommendation, Taylor Collison cites the company’s two FDA-approved respiratory products, Bronchitol for cystic fibrosis and the asthma diagnostic Aridol, which are expected to be profitable on a
Pharmaxis launches share purchase plan to raise approximately A$2 million to fund clinical trials and for working capital
The capital raise is part of its move to bolster its balance sheet as it enters a transformational 12 months with clinical trials of its lead drug PXS-5505 in cancer.
Pharmaxis bolsters balance sheet with $7.2 million placement and $2 million share purchase plan
“Pharmaxis is entering a transformational 12 months with two clinical studies expected to deliver safety and efficacy data in diseases with high unmet need and addressable markets of over $1 billion by the end of 2022," says CEO.
Pharmaxis receives FDA clearance to progress cancer drug to Phase 2 study in liver cancer
“The rapid progression from the compelling pre-clinical work presented for the first time in August to a successful IND submission is very encouraging and we look forward to concluding arrangements for the commencement of the dose escalatio
Pharmaxis attracts A$0.53 price target in coverage initiation from MST Access
“Pharmaxis is entering a potentially transformational period as it advances a portfolio of novel small molecule inhibitors of amine oxidases,” says analyst.
Pharmaxis embarks on phase two bone marrow cancer trial
Bone marrow cancer affects one in 100,000 people, but Pharmaxis’ lead asset could one day help treat patients with this condition.
Pharmaxis cleared to progress to Phase 2 Bone marrow cancer trial
“We are very pleased to have completed the dose-escalation phase of this study with such clear and positive findings,” Pharmaxis CEO Gary Phillips said.
Archive
Pharmaxis’ treatment to prevent wound and burns scars clears phase1 trial
“We will be investigating the safety of 3 months’ treatment with PXS‐6302, and exploring if 3 months’ treatment with PXS‐6302, at a dose that we now know will significantly inhibit an enzyme implicated in scar formation, can make a differen
Pharmaxis enters $2.5 million agreement for rights to Orbital inhaler
Pharmaxis will receive an upfront US$250,000 payment for the 12‐month option and a further US$2.5 million if Aptar decides to exercise the option. In doing so, it will also pay Pharmaxis industry-standard royalties on income received for Or